Healthcare stocks have been under pressure from multiple directions at once: rising medical costs squeezing insurer profits, government drug price negotiations cutting into pharmaceutical revenue, looming patent expirations, and uncertainty about how weight-loss drugs will reshape the entire sector. No single factor explains the downturn. Instead, several structural headwinds have converged to make investors cautious about healthcare across nearly every subsector.
Insurers Are Spending More on Patient Care
Health insurers have been hit hard by a surge in medical utilization that began in late 2023 and extended through 2024. After years of relatively low healthcare usage during the pandemic, patients returned to doctors’ offices, scheduled surgeries, and filled prescriptions at higher rates. That spike in demand directly erodes insurer profitability.
The numbers tell the story clearly. In the Medicare Advantage market, gross margins fell 17% from 2023 to 2024, dropping from $1,986 per enrollee to $1,655. Medicaid managed care fared even worse, with gross margins falling 19% to $608 per enrollee. The medical loss ratio for Medicaid managed care (the share of premiums spent on actual patient care rather than kept as profit) climbed from 88% to 91% in a single year. For an industry where a few percentage points determine whether a quarter is profitable, that shift is significant.
Making matters more complicated, the Medicaid population has changed. After pandemic-era protections ended, states began redetermining eligibility for millions of enrollees. Many healthier, lower-cost members cycled off Medicaid, leaving insurers with a sicker, more expensive remaining population. That shift in risk has pressured margins further.
Medicare Advantage Rates Aren’t Keeping Up
Medicare Advantage plans, which cover more than half of all Medicare beneficiaries, depend heavily on reimbursement rates set by the federal government each year. For 2025, CMS announced an average payment increase of 3.70%, translating to roughly $16 billion more flowing to plans overall. On the surface, that sounds like growth. In practice, it hasn’t been enough.
The details within that headline number reveal why. While the base growth rate was 2.33%, a significant chunk of the increase came from rebasing adjustments that don’t necessarily translate to higher per-member payments for every plan. Meanwhile, changes to risk model calculations reduced payments by 2.45%, and shifts in star ratings (which determine bonus payments) shaved off another fraction. When insurers are simultaneously dealing with double-digit increases in utilization costs, a low-single-digit bump in government payments leaves them squeezed from both sides.
Drug Price Negotiations Are Now Real
The Inflation Reduction Act gave Medicare the authority to negotiate prices directly with pharmaceutical companies for the first time. In August 2024, CMS announced negotiated prices for the first 10 drugs, and those lower prices take effect in 2026. The government also plans to begin invoicing manufacturers for inflation-based rebates in late 2025.
For pharmaceutical stocks, this represents a fundamental change. The U.S. has historically been the world’s most profitable drug market precisely because companies could set prices with little government pushback. Now, the negotiation program will expand to more drugs each year, and investors are pricing in not just the immediate revenue losses from the first 10 drugs but the long-term implications of a government that can demand lower prices on any high-spending medication. Even companies whose drugs haven’t been selected yet are trading at lower multiples because the market sees this as a permanent structural change.
Patent Cliffs Are Approaching Fast
Several blockbuster drugs are losing patent protection between 2026 and 2029, which means generic or biosimilar competitors will enter the market and dramatically undercut their revenue. The biggest losses on the horizon include Pfizer’s breast cancer drug palbociclib ($6.4 billion in annual sales, expiring 2027), Amgen and Pfizer’s rheumatoid arthritis treatment etanercept ($5.4 billion, expiring 2028), and Amgen’s cholesterol-lowering evolocumab ($3.6 billion, expiring 2029). In 2026 alone, Merck faces patent losses on its diabetes franchise worth roughly $3.7 billion combined.
Patent cliffs are a normal part of the pharmaceutical business cycle, but the current wave is unusually concentrated among large-cap companies. When investors look at forward revenue projections and see billions in sales about to face generic competition, they discount the stock accordingly, even if the cliff is still a year or two away.
Weight-Loss Drugs Are Reshaping the Sector
The rapid adoption of GLP-1 medications like semaglutide and tirzepatide has created a unique situation where one class of drugs is simultaneously boosting pharmaceutical stocks (for the companies that make them) while threatening revenue across other parts of healthcare. If tens of millions of people lose significant weight through medication, the downstream effects ripple through the entire sector.
Medical device companies are already feeling the impact. Manufacturers of bariatric surgery tools anticipate a dip in procedure volumes as patients opt for medication instead. Sleep apnea device makers face a similar threat, since tirzepatide is in late-stage trials for treating sleep apnea directly, potentially reducing demand for CPAP machines and surgical implants. Companies like Medtronic and Johnson & Johnson have publicly acknowledged expecting temporary declines in surgery volumes.
For hospitals and health systems, the calculus is equally uncertain. Fewer obesity-related surgeries and procedures could reduce revenue, but the timeline and magnitude remain unclear. Investors tend to sell first and wait for clarity later, which has contributed to broad pressure across medical device and hospital stocks even before the full effects have materialized.
Healthcare Valuations Had Room to Fall
Heading into the downturn, the S&P 500 Healthcare Sector was trading at a forward price-to-earnings ratio around 18.5. That’s not dramatically elevated by historical standards, but it left little cushion for negative surprises. When earnings estimates started getting revised downward (because of rising utilization costs, lower drug prices, and patent cliffs), stock prices had to adjust.
Healthcare is often considered a defensive sector, meaning investors buy it for stability during volatile markets. But when the sector’s own fundamentals are deteriorating, that safe-haven appeal fades. Money that might normally flow into healthcare during a broader market selloff has instead moved elsewhere, removing a traditional source of buying support.
Financial Distress Is Rising Among Hospitals
Hospital and health system mergers hit 72 announced transactions in 2024, approaching pre-pandemic levels. But the nature of these deals has shifted in a troubling direction. More than 30% of all transactions in 2024 involved a financially distressed party, an all-time high. The average revenue of the distressed organizations nearly tripled to $401 million, meaning it’s no longer just small rural hospitals struggling. Mid-sized systems are now seeking partners out of financial necessity rather than strategic ambition.
Rising labor costs, lingering pandemic-era debt, and reimbursement rates that haven’t kept pace with inflation have all contributed to this wave of distress. For investors in hospital stocks or health system bonds, the trend signals that operational margins remain thin and vulnerable to further shocks. Even organizations that aren’t in distress are spending more to retain staff and maintain services, leaving less room for the earnings growth that drives stock prices higher.